Arteriosclerosis and Thrombosis, Vol 11, 1231-1236, Copyright © 1991 by American Heart Association

ARTICLES

Reduction in thrombus formation by PG-1 F(ab')2, an anti-guinea pig platelet glycoprotein Ib monoclonal antibody

JL Miller, M Thiam-Cisse and LO Drouet
Department of Pathology, SUNY Health Science Center 13210.

We have recently demonstrated that intraperitoneal injection into guinea pigs of F(ab')2 fragments of PG-1, a murine monoclonal antibody recognizing the guinea pig homologue of human platelet glycoprotein Ib, produces virtually complete functional block of the platelet von Willebrand factor receptor without inducing a hemorrhagic state. To assess the ability of this antibody to protect against thrombosis resulting from laser-induced injury to mesenteric small arteries, we injected guinea pigs with either PG-1 F(ab')2 (2.3 mg/kg) or with buffer alone 24 hours before study. For each animal, four mesenteric vessels were studied consecutively for 15 minutes each. The number of thrombi, time to first thrombus, and time to embolization of first thrombi were recorded. In the control animals most individual vessels had three to four thrombi, whereas in the antibody-treated animals, vessels most frequently had only a single thrombus or even none at all. The mean number of thrombi per vessel in the antibody-treated animals (1.125) was significantly lower than the mean in the control animals (3.40), with p less than 0.001. However, there was no significant difference between groups with respect to time to first thrombus after laser injury. Detachment of thrombi in the control animals occurred in an easily recordable, discrete fashion, with 75% of first thrombi embolizing in less than 5 minutes. In the antibody-treated animals, gradual dissolution rather than discrete detachment was typically observed. In 31% of the vessels studied in these animals, no embolus occurred; for the remaining vessels only 9% of thrombi were observed to embolize within 5 minutes of their formation.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				D. Wu, K. Vanhoorelbeke, N. Cauwenberghs, M. Meiring, H. Depraetere, H. F. Kotze, and H. Deckmyn Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons Blood, May 15, 2002; 99(10): 3623 - 3628. [Abstract] [Full Text] [PDF]

				N. Cauwenberghs, M. Meiring, S. Vauterin, V. van Wyk, S. Lamprecht, J. P. Roodt, L. Novak, J. Harsfalvi, H. Deckmyn, and H. F. Kotze Antithrombotic Effect of Platelet Glycoprotein Ib-Blocking Monoclonal Antibody Fab Fragments in Nonhuman Primates Arterioscler Thromb Vasc Biol, May 1, 2000; 20(5): 1347 - 1353. [Abstract] [Full Text] [PDF]

				O. Gurevitz, A. Goldfarb, H. Hod, M. Feldman, B. Shenkman, D. Varon, M. Eldar, and A. Inbal Recombinant von Willebrand Factor Fragment AR545C Inhibits Platelet Aggregation and Enhances Thrombolysis With rtPA in a Rabbit Thrombosis Model Arterioscler Thromb Vasc Biol, February 1, 1998; 18(2): 200 - 207. [Abstract] [Full Text] [PDF]

				H. Matsuno, O. Kozawa, M. Niwa, and T. Uematsu Inhibition of von Willebrand Factor Binding to Platelet GP Ib by a Fractionated Aurintricarboxylic Acid Prevents Restenosis After Vascular Injury in Hamster Carotid Artery Circulation, August 19, 1997; 96(4): 1299 - 1304. [Abstract] [Full Text]

				M. Sobel, K. E. Bird, R. Tyler-Cross, D. Marques, N. Toma, H. Edward Conrad, and R. B. Harris Heparins Designed to Specifically Inhibit Platelet Interactions With von Willebrand Factor Circulation, March 1, 1996; 93(5): 992 - 999. [Abstract] [Full Text]